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EBV is an oncogenic human gammaherpesvirus which infects B lymphocytes and epithelial cells. New 
virus replication occurs in both cell types and EBV encodes proteins to replicate its own DNA. Selective 
activation of the DNA damage response (DDR) is thought to occur in order for the virus to efficiently 
conserve its DNA sequence. Components of the double strand break homologous repair pathway are 
known to be recruited to viral replication compartments and loaded onto viral DNA to achieve efficient 
and faithful replication of the viral DNA. 
Using an epithelial cell line latently infected with EBV, we demonstrated interactions between the 
phosphorylated replication protein A (RPA) and the viral lytic proteins BALF2 (DNA binding protein) and 
BMRF1 (polymerase accessory factor). However, despite its presence at replication centres, we failed to 
identify its direct interaction with the viral proteins by co-immunoprecipitation and mass spectrometry. 
Analysis of viral gene expression after ATM inhibition suggests that ATM does not promote the 
expression EBV lytic genes and is perhaps inhibitory. However, we did identify a novel interaction 
between BALF2 and the mitochondrial H+-Ca2+ exchanger LETM1, suggesting a new role for BALF2 
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1.1 EBV life cycle 
Epstein-Barr virus (EBV) is a γ-herpesvirus carried by more than 90% of the world population (Rickinson 
and Kieff, 2001). The majority of carriers are infected asymptomatically during childhood; however, the 
virus is associated with infectious mononucleosis in adulthood. As with all herpesviruses, EBV persists for 
the entire lifetime of the host and it does this as a latent infection of memory B lymphocytes (Babcock et 
al, 1998). Here, viral gene expression is down-regulated to only the non-coding RNAs, EBERs and BARTs, 
(known as latency 0) in order to evade immune detection (Rickinson and Kieff, 2001). It is thought that 
the virus passes from person to person by the exchange of saliva followed by direct entry into tonsillar B 
cells. The interaction between the viral gp350 protein and the B cell surface molecule CD21 is 
fundamental in the entry process for the virus (Nemerow et al, 1987). The virus also has the potential to 
enter epithelial cells by co-transfer infection with EBV coated B cells. Direct infection of epithelial cells is 
probably not a naturally occurring event due to the lack of CD21 expression at the cell’s surface 
(Shannon-Lowe et al, 2011). To replicate, the virus must enter its lytic cycle where it expresses most of 
its genome in order to generate new virus particles. This is seen in vivo when EBV carrying memory B 
cells differentiate into plasma cells (Laichalk et al, 2005) and during the differentiation of primary 
keratinocytes (Fedeerle et al, 2007). 
 
1.2 EBV associated malignancies and latency patterns 
EBV is associated with many lymphomas and epithelial malignancies of various origins. The virus was first 
identified in the UK in 1964 by analysis of Burkitt’s Lymphoma samples imported from sub-Saharan 
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Africa (Epstein et al, 1964). Burkitt’s lymphoma, with the endemic form being EBV associated, is a B cell 
carcinoma that is characterised by the presence of a c-Myc translocation which is likely to be responsible 
for the increased proliferation (Taub et al, 1982). Hodgkin’s lymphoma (HL) and extranodal NK/T cell 
lymphoma (ENKTL) are also known to be EBV associated to varying degrees. It has also been shown that 
EBV contributes to the pathogenesis of the epithelial malignancies nasopharyngeal carcinoma (NPC) and 
gastric carcinoma (GC) (Thompson and Kurzrock, 2004). In the immunocompromised host, there are also 
occurrences of EBV-associated post-transplant lymphoproliferative disease (PTLD). The contribution of 
the virus towards these conditions is difficult to confirm, but it is thought that proteins encoded by latent 
genes contribute to the cancer cell phenotype. 
EBV has a distinct pattern of gene expression depending upon the type of malignancy. The key latency 
genes are the nuclear antigen genes (EBNA-1, EBNA-2, EBNA-3 (A, B and C), EBNA-LP), the latent 
membrane proteins (LMP1, LMP2A, LMP2B) and the previously mentioned non coding RNAs (EBERs and 
BARTs). In various combinations, they form the latency patterns latency 0, latency 1, latency 2 or latency 




Figure 1.1 EBV latency phenotypes of the different B cell malignancies 
associated with EBV. EBV encodes different combinations of latency-





1.3 EBV lytic cycle 
Lytic cycle is where the virus replicates its DNA and forms new virions before the lysis of the host cells 
and the release of infectious particles into the surrounding environment. To do this, the virus must 
express its lytic genes which are subcategorised based on the sequence of their expression: immediate 
early, early and late genes (figure 1.2). The key event in the latent to lytic switch is the expression of the 
immediate early gene BZLF1. BZLF1 acts as a transcription factor and has binding sites at the promoters 
of lytic gene waiting to be transcribed (Rooney et al, 1989). The other immediate early gene, BRLF1, also 
acts as a transcriptional activator with each of the pair contributing to the other’s expression (Liu and 
Speck, 2003). Major components of the 30+ early genes are: BALF5 (DNA polymerase), BMRF1 
(polymerase accessory protein), BALF2 (DNA binding protein), BMLF1 (mRNA export factor), BHRF1 (Bcl-2 
homologue) and BGLF4 (protein kinase). BMRF1, BALF2 and BALF5 are known to locate to replication 
compartments within the nucleus of the host cell along with the immediate early proteins. Viral DNA is 
replicated as large concatameric molecules which are later cleaved to produce genomes of roughly 









1.4 EBV and the host  
EBV encodes proteins which enhance its survival my modulating cellular conditions within the host cell. 
During latency, EBNA-2 and EBNA-LP work together to drive the cell into the G1 phase of the cell cycle by 
binding p53 protein (Szekely et al, 1993). LMP1 is capable of mimicking CD40 at the B cell surface 
therefore resulting in greater cell growth (Zimber-Strobl et al, 1996). The viral BCRF1 gene encodes an 
IL10 homolog which acts as an immunosuppressive cytokine that deters the action of T lymphocytes and 
macrophages which would be clearly advantageous to the occupying virus (Slobedman et al, 2009). 
There is also evidence that EBV has some effect on the cell during its lytic cycle. One cellular aspect that 
is currently under intense investigation is EBV’s relationship with the DNA damage response.  
Figure 1.2 Summary of EBV genes expressed in lytic cycle. Immediate early genes 
BZLF1 and BRFL1 are expressed first then induce each others expression and the 
expression of the other lytic genes. Early genes are subsequently expressed and 
are involved in the replication of viral DNA and modulating the host cell. This is 
followed by the expression of late genes encoding capsid and glycoproteins for 
viral DNA packaging.   
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1.5 Cellular DNA damage 
Individual cells are subject to tens of thousands of DNA damage lesions in any given day. These lesions 
may be induced by either endogenous or exogenous factors. Endogenous factors include DNA 
mismatches from ordinary replication or strand breaks that arise from topoisomerase errors (Jackson 
and Bartek, 2009). Reactive oxygen species (ROS) are a product of oxidative respiration and can induce 
chromosomal instability. ROS are also deployed by cells of the innate immune system as a mechanism of 
defence against infection (Kawanishi et al, 2006). ROS can impair DNA replication and induce base loss 
and single strand breaks (SSBs). When two SSBs are in close proximity, they may form the more toxic 
type of DNA damage, a double strand break (DSB). Exogenous inducers of DNA damage include UV light 
and ionising radiation. Ionising gamma radiation (e.g. from medical diagnostics from X-rays) can induce 
various forms of DNA damage including DSBs (Ward, 1990). 
 
1.6 The DNA damage response 
The DNA damage response (DDR) is a network of signalling pathways which have evolved to repair such 
breaks described above and preserve genome sequences to pass on to daughter cells. Members of the 
DDR can be divided into 4 major categories: DNA damage sensors, signal mediators, signal transducers 
and effectors. The effectors elicit the cellular response which is essentially either DNA damage repair or 
cell death. Dependent upon the type of damage sustained, there are various repair pathways including 
mismatch repair, nucleotide excision repair, SSB and DSB repair. The focus here will be on DSB repair due 
to its known association with viral infections which will be later outlined in further detail. 
Homologous recombination (HR) and non-homologous end joining (NHEJ) are the two major repair 
pathways that can be activated after the detection of a DSB (figure 1.3). The phosphatidylinositol 3-
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kinase-related kinases (PIKKs) ATM and ATR are central mediators to HR repair. During HR, ATM 
autophosphorylates (at serine 1981) and phosphorylates H2AX (γH2AX) as well as components of the 
MRN complex (Mre11-Rad50-Nbs1) which amplify the DDR to recruit further targets including MDC1, 
53BP1 and BRCA1 to repair foci (Derheimer and Kastan, 2010). Single stranded DNA (ssDNA) is then 
generated and coated in RPA which is an ATR target. ATR associates to sites of damage through various 
components including ATR interacting protein (ATRIP) and TOPBP1 (Cimprich and Cortez, 2008). ATM 
and ATR can then phosphorylate CHK2 and CHK1 respectively to activate a cellular response via p53. The 
extensively studied p53 induces transcription of cellular factors involved in inducing apoptosis (e.g. 
PUMA and BAX proteins) and cell cycle arrest (e.g. CDK inhibitor p21). ATM regulation occurs through 
activation of the WIP1 phosphatase of which ATM is a target. HR can only occur during S phase and G2 
due to the requirement of the sister chromatid for template mediated repair. However, NHEJ can occur 
at any stage in the cell cycle. NHEJ is mediated by a third major PIKK, DNA dependent protein kinase 
(DNA-PK) (Burma and Chen, 2004). DSBs are recognised by DNA-PK catalytic subunit, DNA-PKcs, Ku70 
and Ku86, collectively known as the Ku complex, before joining of DNA ends by the recruited DNA ligase 













Figure 1.3 ATM, ATR and DNA-PK signalling pathways in response to DNA double strand breaks. 
During homologous recombination, the MRN complex together with phosphorylated H2AX and 
MDC1 detect DNA damage lesions. The signal is amplified by BRCA1, 53BP1 and others shown 
allowing downstream ATM signalling. RPA binds single stranded DNA and recruits ATR for its 
activation by multiple proteins notably TOPBP1. ATM/ATR signalling leads CHK2/CHK1 
phosphorylation to induce a response cell cycle arrest, DNA repair or apoptosis. DNA can also be 
repaired by non-homologous end joining mechanisms mediated by the Ku complex recruiting DNA 
ligase IV and XRCC4. (Adapted from Turnell and Grand, 2012) 
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1.7 The DNA damage response and DNA viruses 
DNA viruses appear to have a strong relationship with the DDR. A DDR is observed following most viral 
infections although in some cases the advantage to the virus is unclear. It has not been fully determined 
whether the activation of the DDR upon viral infection is due to direct action by the virus or merely a 
consequence of infection. Is the DDR advantageous to the life cycle of the virus or an unwanted and 
inhibitory result of its presence? These are key research questions that are currently trying to be 
answered. As mentioned above, the DDR is a mechanism in place to preserve DNA sequences so they can 
be passed on to the next generation and logic dictates that DNA viruses would want to do the same. 
There is evidence in the literature that supports both arguments. 
For example, there is DDR activation upon initial adenovirus infection with detectable phosphorylation of 
H2AX and RPA32. Later on in infection there appears to be an attenuation of DSB repair pathways which 
occurs by the inactivation of the members of the MRN complex, BLM and DNA ligase IV (Stracker et al, 
2002). However, these DDR targets do not appear to be completely consistent across all serotypes. 
Adenovirus early region 1A (AdE1A) protein up-regulates the expression of p53 as an early event. 
However, AdE1B55K and AdE4orf6 recruit an E3 ligase to polyubiquitinate p53 for 26S proteasome 
mediated degradation. This is thought to occur in order to prevent apoptosis of the host cell curing 
adenovirus infection (Blackford and Grand, 2009). Polyomaviruses have shown a more dependent 
relationship towards the cellular DDR. Polyomavirus large T antigen shares a functional homology with 
AdE1A for example in its role in the activation of p53. During infection, virus production has been shown 
to be significantly decreased in ATM negative cells and in the presence of an ATM inhibitor (Dahl et al, 
2005). Mre11 also co-localises with large T antigen at viral replication compartments during the infection 
of mouse embryonic fibroblasts (Erickson et al, 2012). Papillomavirus infection induces a DDR 
characterised by an increase in phosphorylated ATM with time and genome amplification has also been 
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shown to be dependent on ATM as its inhibition prevents the formation of replication foci (Moody and 
Lamins, 2009).  Herpes Simplex Virus (HSV) has a complex and well-studied relationship with the DDR. 
Infection of fibroblasts leads to increased phosphorylation of ATM, CHK2 and p53. Mre11 and Nbs1 have 
been shown to be recruited to sites of viral replication but other reports show a decrease in Mre11 
expression following infection (Shirata et al, 2005). 
 
1.8 EBV and the DNA damage response 
EBV has a complex relationship with the DDR depending on the context. It has been suggested that the 
virus is capable of inhibiting the DDR to enhance its replication. It has been shown that inhibition of ATM 
favours the transformation of primary B cells into lymphoblastoid cell lines. Within these cells, there is a 
correlation between DDR activation and EBV-induced hyperproliferation which is attenuated by EBNA-3C 
(Nikitin et al, 2010). During lytic cycle, EBV can induce the degradation of p53 via a BZLF1 associated E3 
ubiquitin ligase (Sato et al, 2009). The relationship between EBV and the DDR is not one directional, 
there is also clear evidence for a requirement during the life cycle of the virus. The latent protein EBNA1 
directly induces the release of ROS and therefore facilitates the generation of damage lesions and 
induces a DDR. However, complete DDR signalling is prevented by inhibition of ATM through the action 
of LMP1 (Chen et al, 2008). Thus, it is probable that EBV requires the upstream DDR components such as 
the damage sensors and mediators rather downstream signal transducers and effectors. There is 
evidence to support this selective activation but the relationship is not fully characterised. 
It has been suggested that BZLF1 promoter activation requires ATM activity, although this is not 
universally acknowledged (Kudoh et al, 2005; Li et al, 2011). Subsequent to this work, it has been shown 
that BGLF4 activation leads to ATM-mediated DDR via the phosphorylation of histone acetylase TIP60 (Li 
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et al, 2011) as outlined in figure 1.4. Recruitment of HR proteins such as Rad51 and H2AX to newly 









Figure 1.4 ATM’s contribution to theEBV lytic cycle. ATM is activated by the action of 
ROS, DSBs and acetylation by TIP60. pATM (ser1981) then contributes to the 
activation of the BZLF1 promoter. BZLF1 (Z) induces the other immediate early gene, 
BRLF1 (R), both of which induce the early gene BGLF4 (PK). BGLF4 is then responsible 




Several different DNA viruses, including EBV have been shown to utilise components of the DNA damage 
response in order to replicate their genomes efficiently. Induction of the EBV lytic cycle is usually 
examined in inappropriate cell lines induced into the lytic cycle in a non-physiological manner. However, 
primary differentiated tonsillar epithelial cells do not require such induction because they are naturally 
lytic. We therefore aim to determine if EBV requires elements of the DDR in a physiologically appropriate 
cellular background. Our main aims for this project are as follows: 1) Determine if EBV lytic cycle initiates 
a DDR during lytic cycle. 2) Determine which components of the DDR are being induced by the EBV lytic 
cycle. 3) Determine if EBV proteins directly interact with components of the DDR. 4) Determine the role 












2. MATERIALS AND METHODS  
2.1 Cells and tissue culture 
HEK293, 2089-293, 293-BGLF4KO and Akata cells were maintained in complete medium (RPMI-1640, 
10% foetal calf serum (FCS), 1% glutamine and 1% penicillin/streptomycin). 2089-293 and BGLF4KO-294 
are HEK293 cells containing recombinant B95.8 strain EBV bacterial artificial chromosome (BAC) which 
encodes a hygromycin-resistance and GFP cassette. Akata-GFP is a recombinant Akata strain EBV BAC 
maintained in EBV-loss Akata BL cells encoding a G418-resistance and GFP expression cassette. The 
2089-293 and BGLF4KO-293 medium was supplemented with 100g/ml Hygromycin (Sigma) and the 
Akata-GFP medium was supplemented with 50g/ml G418 cells to maintain the BAC in the cell lines. The 
BGLF4-293 cells were kindly provided by H.J. Delecluse. Tonsils were obtained from the Human 
Biomaterials Resource Centre (HBRC), Birmingham, following routine tonsillectomies. Primary epithelial 
cells derived from tonsils were maintained in Keratinocyte-SFM medium (Life Technologies).  
 
 
2.2 Induction of EBV lytic cycle and transfections 
The EBV lytic cycle was induced by transfecting the 2089-293 (BGLF4KO-293) cells with a plasmid 
encoding the immediate early inducer of viral lytic replication, BZLF1. One microgram of the BZLF1 (pRA) 
and the gp110 (p509) expression plasmids were incubated with 6l of Lipofectamine (Life Technologies) 
in 100l OptiMEM (Life Technologies) at room temperature for 30 minutes. The transfection mix was 
topped up to 1ml with OptiMEM and added to 2x106 2089-293 cells in 1 well of a 6-well plate. The cells 
were incubated with the transfection mix for 3 hours at 37C then topped up with 1ml complete 
medium. The induced 2089-293 cells were harvested at appropriate times following transduction. EBV-
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negative 293 cells transfected with BALF2, BMRF1, BMLF1 or BGLF4-HA plasmids (all cloned into pcDNA3 
expression vectors) underwent the same method of transfection and harvested at 24 hours. Semi-
confluent Akata cells were resuspended at 4x106 cells/mL in RPMI-1640 1% FCS and supplemented with 
goat anti-human IgG (Fab’)2 at 0.5% v:v (50g/ml). The cells were incubated for 3 hours at 37°C then 
diluted to 1x106 cells/mL with complete medium. The virus-containing medium was harvested 72 hours 
post induction and quantified.  
 
2.3 Virus purification and infection of primary keratinocytes 
Purification of infectious virus particles was carried out in order to enhance entry into primary 
keratinocytes. A 60% solution of OptiPrep was diluted to give a 30% solution with OptiPrep diluent 
(0.85% (w/v) NaCl, 60mM Hepes-NaOH, pH 7.4). Two polyallomer ultracentrifuge tubes were made up as 
follows: One mL of 30% OptiPrep was overlaid with 10ml Akata virus supernatant and ultracentrifuged 
using a SW40 swing rotor for 2 hours at 20,000RPM, 4°C. This concentrated the virus on an Optiprep 
cushion. Nine ml of virus supernatant was removed and discarded and the remaining 2ml virus plus 
Optiprep from both tubes were thoroughly mixed and placed in a 4.8mL ultracentrifuge tube, topped up 
with 15% Optiprep. The virus was then ultracentrifuged in a vTi60.5 vertical rotor for 2 hours 30 minutes 
at 64,000RPM, 4°C to generate a density gradient in which the intact virus bands. The single white band 
of intact virus was removed by needle and syringe. The virus was then diluted 1 in 10 with Keratinocyte 
SFM.  
Primary keratinocytes were initially incubated with integration-deficient CD21-expressing lentivirus 
(provided by C. Shannon-Lowe) to facilitate CD21-mediated viral entry. The lentivirus was removed after 
24 hours at maximal CD21 expression and replaced with purified Akata virus supernatant for 24 hours. 
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The GFP-positive epithelial cells were sorted by FACS for GFP expression as a marker of EBV infection. 
The cells were then harvested for RNA analysis. 
 
2.4 Antibodies 
Antibodies used to detect EBV proteins by immunofluorescence and Western blot are shown in table 
2.1. Antibodies to detect DNA damage response proteins are shown in table 2.2. All antibodies for 
immunofluorescence (IF) were diluted in 10% heat inactivated normal goat serum (HINGS) and 
antibodies used for WB were diluted in 5% w/v dry milk powder in TBS-Tween except where stated 
otherwise.  
Target Clone Species Application (dilution) Provider/Reference 
BZLF1 BZ.1 Mouse IF (1/50), WB (1/1000) M. Rowe 
BRLF1 11-008 Mouse IF (1/500), WB (1/1000) Argene 
BHRF1 5B11 Mouse IF (1/200), WB (1/100) Chemicon 
BGLF4 RB03734 Rabbit IF (1/100), WB (1/200), IP Abgent 
BMRF1 R3 Mouse IF (1/200), WB (1/2000), IP Chemicon 
BMLF1 EB2 Rabbit IF (1/100), WB (1/5000), IP Buisson et al, 1999 
BALF2 OT13-B Mouse IF (1/2000), WB (1/4000), IP J. Middeldorp 
BALF5 - Rat IF (1/100), WB (1/1000) F. Grasser 
 
 Table 2.1. Antibodies used in this study to examine EBV lytic gene expression. All 




Target Clone Species Application (Dilution) Provider/Reference 
ATM D2E2 Rabbit WB (1/1000)* Cell Signalling 
ATM AB82512 Rabbit IF(1/200) Abcam 
pATM (Ser1981) AB81292 Rabbit IF (1/200) Abcam 
pATM (Ser1981) 10H11.E12 Mouse WB (1/1000)* Cell Signalling 
ATR E1S3S Rabbit WB (1/1000) Cell Signalling 
pATR (Ser428) 2853 Rabbit WB (1/1000)* Cell Signalling 
p53 D01 Mouse WB (1/200) R. Grand 
Mre11 4895 Rabbit WB (1/1000) Cell Signalling 
H2AX  D17A3 Rabbit IF (1/1000), WB (1/1000)  Cell Signalling  
γH2AX (Ser139) JBW301 Mouse WB (1/1000) Millipore 
γH2AX (Ser139) AB11174 Rabbit WB (1/1000)  Abcam 
Rad50 AB3623 Rabbit IF (1/100), WB (1/1000) Abcam 
Rad51 H-92 Rabbit IF (1/50), WB (1/1000) Cell Signalling 
RPA32 AB-2 Mouse WB (1/1000)   Calbiochem 
RPA32 A300-244A Rabbit WB (1/1000) Bethyl 
pRPA (Ser4/Ser8) A300-245A Rabbit IF (1/1000), WB (1/1000)*  Bethyl  
NBS1 AB7860 Mouse WB (1/1000), IF (1/100)  Abcam 
pNBS1 (Ser278) AB111373 Rabbit WB (1/1000) Abcam 
CHK2 - Rabbit WB (1/1000)  G. Stewart 
 
 
Table 2.2. Antibodies used in this study to examine DNA damage response proteins. All 
antibodies are shown at the dilutions used for either Western blot of immunofluorescence. *5% 




Target Clone Species Application (Dilution) Provider/Reference 
Actin  AC-40 Mouse WB (1/4000)  Sigma 
Calregulin  C4606 Rabbit WB (1/2000) Sigma 




Target Species Application (dilution) Provider/Reference 
Rat IgG (Alexa-Fluor-488) Goat IF (1/1000) Life Technologies 
Mouse IgG (Alexa-Fluor-488) Goat IF (1/1000) Life Technologies 
Mouse IgG (Alexa-Fluor-594) Goat IF (1/1000) Life Technologies 
Rabbit IgG (Alexa-Fluor-488) Goat IF (1/1000) Life Technologies 
Rabbit IgG (Alexa-Fluor-594) Goat IF (1/1000) Life Technologies 
Mouse IgG (HRP conjugated) Goat WB(1/1000) Sigma 
Rabbit IgG (HRP conjugated) Goat WB (1/2000) Sigma 





Table 2.3. Antibodies used in control experiments. All antibodies are shown at the 
dilutions used for either Western blot of immunofluorescence.  
 
Table 2.4. List of secondary antibodies. All antibodies are shown at the dilutions 




2.5 Western blotting 
Cells were removed of growth medium and washed with sterile PBS before harvesting and dilution in 9M 
urea. These samples were then lysed by sonication and the concentration was determined by 
absorbance readings relative to 1ug/ul BSA. 20ug of sample was loaded (with equal volume gel sample 
buffer (9M urea, 50mM Tris HCl pH 7.4, 10% SDS, 0.15M β-mercaptoethanol, 0.1% bromophenol blue) 
onto an acrylamide gel. Gels were then wet transferred onto nitrocellulose membrane in transfer buffer 
(0.05M Tris, 0.19M glycine, 20% methanol) at 280mA for 6 hours. Membranes were blocked for 1 hour 
with 5% w/v dry milk or 5% w/v BSA in TBS-Tween before incubation with primary antibodies overnight 
at 4°C. Following washing, secondary antibodies (HRP linked) were incubated with the membranes for 2 
hours at room temperature. A final TBS-Tween washing stage precede the addition of ECL reagent for 1 
minute followed by detection of bands via X-ray film. 
 
2.6 Co-immunoprecipitation (Co-IP) 
For each IP experiment (including controls), 2x107 cells were harvested, pelleted and kept on ice. The 
pellet was resuspended in 1mL NETN buffer (1% NP40, 0.15M NaCl, 5mM EDTA, 50mM Tris, pH to 7.4) 
and lysed with a Wheaton-Dounce homogeniser. The following centrifugation steps then took place 
saving the supernatant at each step: 5 minutes at 3000RPM, 5 minutes at 13000RPM, 30 minutes at 
45000RPM. The supernatant was then incubated with 5ug of antibody overnight at 4°C followed for a 
further centrifugation at 45000RPM. The samples were then incubated for 2 hours with 50ul of Protein G 
beads per 1mL of supernatant and spun for 2 minutes at 3000RPM, discarding the supernatant and then 
washing the pellet with NETN buffer. The final pellets were resuspended in 50ul gel sample buffer, boiled 
at 85°C for 3 minutes and loaded on to a 10% acrylamide gel for Western blot analysis.  
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2.7 Mass Spectrometry 
Cells were harvested and treated in the same manner as co-immunoprecipitation samples with the 
exception of the final resuspension in gel sample buffer and Western blot analysis. The pellets were 
instead washed twice with detergent-free NETN buffer and then denatured in 9M Urea/50mM 
ammonium bicarbonate (ABC) for 30 minutes at room temperature. After centrifugation, protein was 
collected from the supernatant and reduced with 50mM dithiothreitol (DTT) in 50mM ABC for 30 
minutes at 56°C and alkyated with 100mM iodoacetamide (IAA) for 30 minutes at room temperature in 
the dark. The protein was recovered using Amicon centrifugal filters (30K cut off) which were washed 
four times with 50mM ABC. Protein was then digested with 1ug of sequencing grade trypsin overnight at 
37°C added to the washed filters. The peptides were retrieved by centrifugation of the filters which were 
washed with 300µL of ABC. Combined supernatants containg the tryptic peptides were dried in a 
vacuum centrifuge, resuspended in 1% acetonitrile/1% formic acid and loaded onto the mass 
spectrometer.  
 
2.8 RNA extraction, DNase digestion and cDNA synthesis 
RNA was extracted from the cells using the Nucleospin II kit (Macherey-Nagel) according to 
manufacturer’s instructions. The RNA was subjected to a further DNAse treatment to remove all 
remaining DNA using the DNAfree kit (Ambion, Life Technologies). One microgram of RNA was incubated 
with 1l DNase at 37C for 30 minutes then inactivated with the inactivation solution for 2 minutes. The 
RNA samples were centrifuged to remove the inactivation solution and 10l (400ng) was removed for 
the cDNA synthesis. The treated RNA was added to 4l Q-Script (VWR) and incubated at 42C for 1 hour 
followed by inactivation at 95C for 5 minutes to give a final concentration of 5ng/l of cDNA.  
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A recombinant plasmid containing 45 EBV amplicons and 3 cellular amplicons (known as the absolute 
quantification (AQ) plasmid) (see appendix I) was cloned into a pUC57 vector (GenScript) and used to 
generate a standard curve for qPCR. FAM/TAMRA labelled Taqman real-time PCR assays were designed 
for each individual EBV gene. The three control assays included Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), Beta-2-microglobulin (B2M) and Phosphoglycerate kinase 1 (PGK1) (Life 
Technologies). 25ng of test sample DNA and 10 fold dilutions of the quantification plasmid were used to 
amplify the target genes. Specific target amplification was carried out on 25ng of DNA using 1.25µL 
primer mix (45 EBV and 3 cellular) and PreAmp Master Mix (Life Technologies) in DNA suspension buffer 
(10mM Tris, pH 8.0, 0.1mM EDTA) as instructed. After 95C heating for 10 minutes, samples underwent 
12 cycles of 95C for 15 seconds followed by 60C for 4 minutes. 1 in 5 dilutions were prepared and 
loaded on to 48:48 Dynamic Array IFC (Fluidigm), run in a Biomark HD machine and analysed using 
Biomark Real-Time PCR Analysis Software Version 2.0. 
 
2.9 Immunofluorescence microscopy 
Following EBV infection or lytic cycle induction, cells were trypsinised and incubated overnight at 37°C on 
fibronectin coated 8-well chamber slides (2x104 cells per well). The cells were fixed with 4% 
paraformaldehyde (PFA) for 20 minutes at RT, permeabilised with 0.5% Triton X-100 for 5 minutes at RT 
then blocked in 10% HINGS for 1 hour at RT. The cells were then incubated with diluted primary 
antibodies for 1 hour at 37C, thoroughly washed in PBS then incubated with the appropriate secondary 
antibodies. Slides were then mounted in DAPI-containing Vectashield mounting buffer (Vector labs). The 




2.10 Induction of DNA damage and inhibitor treatments 
To induce DNA damage for positive controls, confluent cells were treated with ionizing γ-rays from a 
137Cs source at a dose of 6Gy radiation. After 1 hour at 37C, cells were fixed with 4% PFA for 
immunofluorescence microscopy as above or harvested for either western blot or RT-qPCR analysis. 
 
For ATM inhibitor treatment experiments, cells were treated with either 0µM (DMSO only), 1µM, 5µM or 
10µM of the inhibitor KU55933 (Calbiochem) for 1 hour. Cells were harvested for analysis by RT-qPCR, 
western blot or counted to quantify cell viability which was determined by uptake of Trypan Blue. 













3. RESULTS  
 
3.1 EBV lytic protein expression and the ATM/ATR response 
We initially wanted to determine when the EBV genes of interest were expressed following induction 
into lytic cycle. 2089 cells were induced into lytic cycle by transfection with BZLF1 and harvested at 0, 12, 
24, 48 and 72 hours post induction and subjected to Western blotting (figure 3.1). The gp110 expression 
vector (pRA) was co-transfected with the BZLF1 expression vector (p509) in order to produce complete 
and infectious virus particles as the 2089 sequence contains a small deletion in the gp110 gene. 
Expression of the immediate early and early proteins analysed, began between 12 and 24 hours post 
induction and then increased throughout the entire time course. The 0 hour time point represents a no 
plasmid transfection. The transfected BZLF1 is expressed at 24 hours and stimulates the expression of 
the other immediate early gene, BRLF1. These stimulate the expression of the early lytic genes which are 
involved in the replication of viral DNA. All proteins are significantly expressed by 48 hours. There is no 







Figure 3.1 Analysis of EBV lytic gene expression. A) 2089 cells induced 
into lytic cycle by transfection of p509 (BZLF1) and harvested at the 
indicated time points. Western blot analysis was used determine 
protein levels of immediate early (BZLF1, BRLF1) and early proteins 
(BMRF1, BALF5, BMLF1 and BALF2). B) Cells were also subject to qPCR 
analysis by the 48:48 Dynamic Array IFC following RNA extraction and 
cDNA generation. Transcripts of the indicated genes were measured. C) 
Primary keratinocytes were infected with CD21-expressing lentivirus for 
24 hours followed by infection with Akata-GFP virus and sorted based 
on GFP positivity. Cells were harvested and RNA extracted before for 




To compare the dynamics of EBV lytic replication in a more physiologically relevant model, primary 
keratinocytes were obtained for analysis following routine tonsillectomies. Once in culture, cells began 
to differentiate, making it possible for EBV to undergo lytic cycle once the virus has entered. To facilitate 
entry of the virus, cells were infected with CD21-expressing lentivirus as this protein is known to be 
essential for B cell infection (Nemerow et al, 1987). After a 24 hour incubation period, cells were then 
washed and infected with recombinant Akata (GFP-positive) strain EBV for 24 hours and sorted for GFP 
positivity to purify the cells of interest. Cells were then harvested immediately or cultured a further 24 
hours (48 hours post EBV infection) and then harvested. RNA was extracted from cells and cDNA 
generated for qPCR analysis using a 48:48 Dynamic Array IFC as described in materials and methods. 
Gene expression is shown for the major lytic genes BZLF1, BRLF1, BHRF1, BMLF1, BALF1, BALF2, BGLF5 
and GP350 (figure 3.1C). 2089 cells harvested at 0, 12, 24, 48 and 72 hours were subjected to the same 
qPCR analysis (figure 3.1B). 
Gene expression was relatively low compared to the 2089 model and the data were normalised to 
GAPDH transcripts. No obvious host cell protein synthesis shut off was observed. Expression appears to 
be higher at 24 hours rather than at later time points as previously seen in our cell line. A 2-fold decrease 
is apparent in all gene transcript levels at 48 hours. This is also true for each subset of the lytic genes: 
immediate early, early and late. Due to the low number of cells available for this experiment, it was not 
possible to carry this out in duplicate and a 72 hour time point could not be investigated. Due to 
circumstances out of our control, no further experiments could be carried in these cell types. 
In order to determine the time after lytic induction that the viral proteins involved in viral DNA 
replication may affect the DNA damage response, we performed a time course experiement for 72 
hours. The harvested cells were subjected to Western blot analysis for H2AX, Nbs1, ATM, CHK2, RPA, 
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ATR and their phosphorylation at damage associated sites examined. 2089 cells were transfected with 
BZLF1 and with or without gp110. Cells subjected to transfection of gp110 only acted as a negative 
control for DDR activation. No lytic gene expression was observed with the transfection of gp110, 
therefore any response in this subset is attributable to the cells responding to the presence of foreign 
DNA.  
ATM and its selected down-stream targets H2AX, RPA and CHK2 (including their phosphorylated forms) 
were identified as seen in figure 3.2. Over time, the phosphorylation of H2AX (seen as γH2AX) increases  
significantly, from virtually no detectable protein at 0 hours, indicating a damage response has been 
activated. There may be a slight upregulation in ATM expression over time but not greatly. ATR and its 
downstream target, RPA, were also detected as well as DNA damage associated phosphorylation. A slight 
increase in RPA expression is detectable at 48 and 72 hours post transfection where we see expression of 
immediate early and early EBV lytic genes as shown in figure 3.1A and B. In the mock transfected cells, 
the total (and phosphorylated) protein expression trends are mirrored in each case for both ATM, ATR 
and their downstream targets. These trends cannot therefore be solely attributed to action of viral 
proteins. A notable result is the phosphorylation of Nbs1, at 12 and 24 hours post induction, in the mock 















Figure 3.2 Analysis of the DNA damage response during lytic replication. 2089 cells 
induced into lytic cycle by transfection of p509 (BZLF1) and pRA (gp110) and harvested 
at the indicated time points. Western blot analysis was used determine protein levels 




3.2 Co-localisation of EBV lytic proteins and components of the DNA damage response  
Given that induction into lytic cycle did appear to alter expression or phosphorylation of DDR proteins 
relative to our controls, we decided to investigate the localisation of both viral cellular DDR proteins in 
lytic cells. A representative panel of DDR proteins was investigated by immunofluorescence microscopy 
during EBV lytic cycle. Initially, the proposed antibodies to be used for these experiments were tested for 
their ability to detect damage foci and were optimised using 293 cells. 293 cells grown on chamber slides 
were treated with 6Gy of gamma-radiation or left untreated, fixed after 1 hour and stained as 
appropriate (figure 3.3). The irradiated cells clearly show the formation of damage foci, due to the 
induction of DSBs, by the recruitment of γH2AX, pATM and NBS1 to specific compartments within the 
nucleus relative to the untreated cells. There is less obvious formation of foci with pRPA, Rad50 and 
Rad51 but a clear difference in staining pattern when compared to unirradiated cells. Other candidates 
were also tested (data not shown) but showed no difference between untreated and irradiated cells and 









Figure 3.3 Optimisation of antibody concentrations. 293 cells were 
treated with either 6Gy radiation or left untreated and fixed after 1 
hour. At varying concentrations, slides were then stained for DNA 
damage foci associated proteins pRPA, γH2AX, pATM, Rad50, Nbs1 and 




In order to investigate the co-localisation between EBV lytic proteins and DNA damage components, 
2089 cells were induced into lytic cycle as previously described and plated on to chamber slides for 
immunofluorescence staining and fixed at 24 hours post induction. Cells were then either stained for the 
viral DNA binding protein, BALF2, or the viral polymerase accessory protein, BMRF1, with various anti-
DDR antibodies. These viral proteins were chosen for their central role in viral DNA replication. 
Representative immunofluorescence experiments are shown (figures 3.4 and 3.5). Each figure shows the 
localisation of pRPA, Rad51, pATM and Rad50 in lytic 2089 cells. For each pairing of proteins, the 
immunofluorescent image has been shown with a merge to visually analyse co-localisation by the 
presence of pixels expressing yellow, a false colour representing co-localised proteins. Viral replication 
compartments are known to occur in the nucleus, therefore the pixels representing the nucleus have 
been analysed as our region of interest (ROI) for the scatter graphs shown. The scatter graphs allow the 
isolation of pixels expressing intensity of ≥50% of maximal intensity (regions 1, 2 and 3) for analysis. This 
was done to differentiate between background and real and specific protein staining. Region 3 pixels 
represent co-localisation. Co-localisation coefficients are calculated based on co-localised pixels as a 
proportion (minimum: 0, maximum: 1) of total intense pixels for each colour (i.e. protein).  Region 1 and 









 Figure 3.4 Co-localisation of BALF2 with DNA damage proteins. 2089 cells were induced into lytic 
replication and fixed onto slides at 24 hours post induction. Cells were then stained for BALF2 (red) and 
either A) pRPA B) Rad51 C) pATM or D) Rad50. Co-localisation coefficients were then calculated based on 





 Figure 3.5 Co-localisation of BMRF1 with DNA damage proteins. 2089 cells were induced into lytic 
replication and fixed onto slides at 24 hours post induction. Cells were then stained for BMRF1 (red) and 
either A) pRPA B) Rad51 C) pATM or D) Rad50. Co-localisation coefficients were then calculated based on 




There is a strong association between pRPA and BALF2 localisation (figure 3.4A). The staining shows a 
high level of co-localisation between the two proteins but in the absence of distinct foci or replication 
compartments. The images selected are representative of the staining pattern throughout but there was 
some variation in the presence or absence of distinct foci between cells. Analysis of the scatter graphs 
here shows that a significant proportion of the highly intense pixels have co-localised. The coefficients 
determined that 98.7% of the pixels showing staining for pRPA are also staining for BALF2 (and vice versa 
for the BALF2 pixels at 81.2%). Such intense staining for pRPA was not seen in non-lytic lytic cells. A 
similar relationship is evident between BALF2 with pATM (figure 3.4C) but to a lesser extent. Here, 
proportionally, there are many more pixels staining at a high intensity that are independent from each 
other compared to the relationship seen for BALF2 and pRPA. Figures 3.4B and 3.4D show the lack of co-
localisation of BALF2 with Rad51 and Rad50 respectively. Very few pixels, if any, are staining with a high 
enough intensity to suggest real staining rather than background. In each case BALF2 is only showing a 
co-localisation coefficient of 0.001 for Rad51 and 0.000 for Rad50.  
BMRF1 was co-stained with the same cellular proteins for comparison and similar results are seen in 
certain circumstances. A high intensity of staining is present in the nuclei of lytic cells for pRPA (figure 
3.5A) and again shows a close association with the viral protein. A different pattern of pATM staining 
(figure 3.5C) is observed when co-stained with BMRF1. The images suggest very little co-localisation is 
occurring, which is confirmed by the low coefficient values. The distribution of pATM does not seem to 
differ between the lytic cells and surrounding cells that have not entered lytic cycle. Figures 3.5B and 
3.5D show staining for Rad51 and Rad50 with BMRF1, respectively. Similar patterns are seen here as 
with BALF2, however these DDR proteins have not stained strongly enough in this case to confidently 
identify specific staining from background. Little association is visible within the images and these 
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correspond to the low coefficient values. BMRF1 appears to be present in the cell independently of both 
Rad51 and Rad50.  
 
3.3 Interactions between viral and cellular DDR proteins 
In order to determine if the co-localisation of the viral proteins with the DDR proteins, RPA in particular, 
corresponds to a physical interaction, we performed co-immunoprecipitation (co-IP) experiments. Again, 
2089 cells were induced into lytic cycle with BZLF1 and harvested at 24 hours and subject to co-IP. Cell 
lysates were incubated with antibodies against BMRF1, BALF2 (fig 3.6A) and BMLF1 (fig 3.6B). 
Immunoprecipitated proteins were retained on Protein G beads before Western blot analysis. γH2AX 
was also blotted for due to its previously reported association with EBV lytic cycle (Kudoh et al, 2009). 
No-antibody samples were included as negative controls and 10µg of 293 lysate was loaded as a positive 
control for the DNA damage proteins. The presence of a band in the negative control lane for RPA in 
figure 3.6A makes the analysis more difficult, but there seems to be no difference between the control 
samples and the test samples for BMRF1 and BALF2. This is also true for γH2AX. Figure 3.6B shows the 
presence of a faint band at a long exposure for RPA in the BMLF1 sample which is not present in the 
negative control.  
Co-IP studies were also carried out in order to determine whether viral proteins could interact with RPA 
and γH2AX independently of the lytic cycle. This was done in order to determine if any interactions 
observed from the 2089 cells were dependent on other viral proteins. 293 cells were transfected (or left 
untransfected for negative controls) with plasmids containing either BMRF1 (figure 3.6C), BALF2 (figure 
3.D), BMLF1 (figure 3.6E) or BGLF4 (HA tag) (figure 3.6F). After 24 hours the cells were harvested, lysed, 
incubated with appropriate antibody and analysed by Western blot for RPA and γH2AX binding. An anti-
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HA antibody was used to immunoprecipitate BGLF4. Again, 10µg of 293 cell lysate was used as a positive 
control for the DDR antibodies. As a negative control, the same viral antibody was used but with the 
lysate of untransfected 293 cells (panel C to F). In each case, no obvious difference was observed 
between negative control and test samples. This is significant for BMLF1 and RPA which in previous 
analysis have given a positive result (figure 3.6B).  
 
 
Figure 3.6 Interactions 
between RPA and 
γH2AX with viral lytic 
proteins. A and B: 2089 
cells induced into lytic 
cycle by transfection of 
p509 (BZLF1) and 
harvested at 24 hours. 
Antibodies against 
BMRF1, BALF2 and 
BMLF1 were used to IP 
followed by Western 
blot analysis. C to F: 293 
cells transfected with 
plasmids for BMLF1, 
BMRF1, BGLF4 (HA), 
BALF2 or transfected 
and harvested at 24 
hours. The appropriate 
antibody was used to IP, 
alongside untransfected 
293 controls, followed 
by Western blot 
analysis. 293 lysate was 





To identify further potential interactions for viral proteins with DDR proteins and other cellular 
components, mass spectrometry analysis of induced 2089 cells followed. As previously described, 2089 
cells were induced into lytic cycle and harvested at 24 hours. Lysates were then immunoprecipitated 
with BMRF1, BALF2, BMLF1 or BGLF4. Analysis of samples immunopreciptated by BMRF1, BMLF1 and 
BGLF4 antibodies all failed to detect any viral proteins. However, BALF2 fragments were detected in the 
appropriate sample. After excluding proteins also detected in the no-antibody negative control, no 
known DDR related proteins were observed. The most notable result was an overwhelming 14 identified 
peptides specific to the LETM1 protein. Although LETM1, a mitochondrial H+-Ca2+ exchanger, is not a 
known DDR protein and the result would need to be verified, this is a novel interaction. For comparison 













3.4 The effects of ATM inhibition on EBV gene expression 
ATM is central to the DNA damage response signalling pathways. It has been suggested that it and other 
aspects of the DDR are required for efficient replication of EBV; it is possible, therefore, that ATM 
inhibition will have a negative impact. Initially, the ATM inhibitor (ATMi) KU55933 was tested for 
function at various concentrations suggested in previous reports. 293 cells were treated with 10µL of 
either DMSO alone, 1µM, 5µM or 10µM (final concentration) of ATMi followed by irradiation and 
harvesting for Western blot analysis (figure 3.7A). As a control, pATM (s1981) and its downstream 
targets pKAP1, and γH2AX were probed to test the level of phosphorylation, ensuring the ATMi was 
working. 293 cells, untreated with ATMi or radiation, were used as a control for a non-activated damage 
response. Most strikingly, the KAP1 phosphorylation decreases to unirradiated levels in the presence of 
5µM ATMi. H2AX and ATM phosphorylation remained a little higher than the unirradiated cells at both 
5µM and 10µM but there is still an evident reduction. 
The toxicity of the ATMi or DMSO treatment was a potential issue which could give misleading results. 
Cells were treated with concentrations of ATMi as above and counted at time points subsequent 
experiments. Cells were counted in the presence of Trypan Blue to determine cell viability. Dead cells, 
which take up Trypan Blue, were counted as a percentage of total cells. Detached cells from the media 
and adherent cells were both counted for accurate measurement. Cells were not split or fed (0 to 72 
hours) following the replacement of the ATMi-containing medium with fresh medium at 1 hour. We did 
not observe an increase in cell death with increased concentration of ATMi (figure 3.7B). Total live cell 
percentage does not drop below 85%. We therefore used the ATMi concentrations and time points 








Figure 3.7 Efficiency and toxicity of ATMi KU55933. A) 293 cells were treated with 
various concentrations of ATMi: 0µM (DMSO-only), 1µM, 5µM or 10µM. After 1 hour, 
cells were treated with 6Gy radiation and harvested after a further one hour. Western 
blot analysis was used to determine phosphorylation levels of appropriate ATM 
targets. B) The cells were treated as above, then viability was assessed using Trypan 




We then investigated if the inhibition of ATM would alter the levels of EBV lytic gene transcripts. 2089 
cells were treated with ATMi for 1 hour then induced into lytic cycle by transfection of BZLF1. The cells 
were harvested every 24 hours over 3 days, cDNA generated and qPCR performed using a 48:48 Dynamic 
Array IFC as described in materials and methods. All samples were measured in duplicate (standard 
deviations shown as error bars) with the exception of the 72 hour DMSO-only sample. The original 
experimental design was to normalise the transcript data in comparison to one of the housekeeping 
genes PGK1, GAPDH or B2M. However this proved not to be possible due to the unexpected reduction of 
the expression of housekeeping genes over time (figure 3.8) possibly due to virally induced shut off of 
host cell protein synthesis. Instead data shown in this section have been presented as transcripts per µL 




Figure 3.8 Transcript levels of PGK1 during lytic induction and ATMi. 2089 cells 
were induced into lytic replication after ATMi treatment and harvested for qPCR 
analysis of generated cDNA. PGK1, shown here, is representative of the trend 
observed with the housekeeping genes. 
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EBV transcript levels were analysed with the same samples (figure 3.12). Transcripts of all EBV genes 
increases over time as expected due to the continual expression of BZLF1. BZLF1 expression is shown in 
figure 3.9A. Very little difference is seen between BZLF1 expression at 24 hours with DMSO, 1µM and 
5µM samples. However there is then a 5-fold increase from 5µM to 10µM at this time point. At later 
time points, lower concentrations of the ATMi seem to have an effect on BZLF1 transcript levels. The 
three test concentrations of the ATMi have comparable results of around 2.5 to 3-fold increase relative 
to the DMSO-only sample. The 48 hour samples show a distinct pattern in between the other time points 
because in this case the major increase in transcript level seems to occur between 1µM and 5µM. Here 
we see a 6-fold increase in number of transcripts per µL. 
Transcriptional analysis of the other immediate early gene, BRLF1, is shown in (figure 3.9B) and showed 
a significantly lower level of expression than BZLF1, probably due to the fact the BZLF1 gene is 
overexpressed as it has been transfected into the cells using a plasmid vector. The two major trends are 
similar to that observed for BZLF1: expression increases over time and expression increases with higher 
concentrations of ATMi. The changes are noticeably more gradual with 0 to 2-fold differences between 
each time point at each concentration. Slight changes are also apparent for BHRF1 expression (figure 
3.9C) where there is a great increase from 48 hours to 72 hours in gene expression; however, this is also 
seen in the DMSO control and not attributable to the inhibitor.   
Changes in gene expression level for BMLF1 (figure 3.9D) and BMRF1 (figure 3.9E) are minimal and 
comparable data points are not significantly different from each other. BMLF1 expression at 72 hours 
appears abnormally low considering the two major trends throughout these results but this is likely to be 
an anomaly. BALF1 (figure 3.9F), BALF2 (figure 3.9G) and BGLF5 (figure 3.9H) show very little expression 
at 24 hours at all ATMi concentrations but there is a 3-fold change from DMSO control to 10µM.  
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GP350 was also analysed to determine whether structural genes were undergoing the same pattern as 
the immediate early and early gene transcripts (figure 3.9I). At 24 hours, there seems to be low levels of 
expression of this late gene but this was still surprisingly high when compared to certain early genes such 
as BALF1. The two major trends also applied here but only less than 2-fold changes were seen at any 






Figure 3.9 EBV transcript levels during lytic induction and ATM inhibition.  
2089 cells were treated with various concentrations of ATMi then induced 
into lytic cycle. Cells were harvested at 24, 48 and 72 hours post induction 
and lysates were used to generate cDNA for qPCR analysis. Transcript levels 
shown for A) BZLF, B) BRLF, C) BHRF1, D) BMLF1, E) BMRF1, F) BALF1, G) 
BALF2, H) GP350, and I) BGLF5. Data shown as transcripts per µL. 
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3.5 Activity of the viral kinase, BGLF4, during lytic replication 
The virally encoded kinase, BGLF4, has previously been reported to be involved in inducing a DNA 
damage response by indirectly activating ATM. In order to examine possible interactions between 
BLGF4 and cellular damage proteins, we performed a co-IP experiment (figure 3.10). 2089 cells were 
induced into lytic cycle and harvested at 24 hours post induction. A no-antibody sample and 293 
lysate (10µg) were used as negative and positive controls respectively. No clear bands are visible in 
the IP lanes for Mre11 or Rad50 relative to the negative control suggesting no BGLF4 interaction has 
occurred with these proteins. An apparent RPA band was observed with the immunoprecipitated 
BGLF4 although it has run at a higher molecular weight than the RPA in the 293 lysate control. 
Distinct staining has occurred at the right sizes for both p53 and NBS1 in the test IP samples. 
Given the apparent interaction between BGLF4 and certain DDR proteins, we decided to further 
investigate the viral kinase by immunofluorescence microscopy. 2089 cells were induced into lytic 
cycle by the transfection of BZLF1, plated on to chamber-well slides and fixed at 24 hours. The cells 
were then co-stained with antibodies against BZLF1 and BGLF4 in order to see if BGLF4 was located 
at replication compartments. The staining results shown in figure 3.11 are representative of the cells 
in lytic cycle and show a distinct pattern of BGLF4 staining adjacent to, and outside, the nucleus. 
BGLF4 appears not to co-localise with BZLF1 within the nucleus as is known to be the case with other 
lytic proteins. Furthermore, not all lytic cells are showing this specific BGLF4 staining pattern and 
most lytic cells are not showing any BGLF4 staining at all. The BGLF4 staining can also be observed in 
distinct foci and concentrated in one generalised area within the cell.  
Immunofluorescence staining prompted us to investigate whether BGLF4 was being exported from 
the nucleus during lytic cycle or if the antibody used was non-specific. Initially, BGLF4-KO cells were 
induced into lytic cycle by BZLF1 transfection, grown on chamber-well slides, fixed after 24 hours and 
stained for both BZLF1 and BGLF4. The same staining pattern was observed as in our BGLF4-KO cells 
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and the 2089 cells (data not shown) therefore the antibody is not suitable for immunofluorescence 
detection of BGLF4. We also tested the suitability of the antibody to detect BGLF4 in Western blot. 
EBV negative 293 cells were transfected with BGLF4 (HA tag) expression vector and harvested at 0, 
24 and 48 hours. The samples were subjected to Western blot analysis and probed with BGLF4 and 
HA antibodies and a band was seen at approximately 48kDa, the reported size of the BGLF4 protein 
(figure 3.12). Bands were detected using the BGLF4 antibody at the correct size and only in the 24 
and 48 hour samples suggesting the antibody is specific to BGLF4 for Western blot. Detection of HA 
at the same size confirmed this finding. However, unexpectedly, BGLF4 was not detected at 48kDa 
within the 2089 cells at the same time points even with long exposure. Although we cannot confirm 
the presence of BGLF4 in 2089 cells with an alternative antibody at this time, the data here could 
suggest BGLF4 cleavage due the presence of a strongly-staining band at lower molecular weight 

























Figure 3.10 Co-immunoprecipitation for the interaction between 
BGLF4 and DDR proteins. 2089 cells induced into lytic cycle by 
transfection of p509 (BZLF1) and harvested at 24 hours. Antibody 
against BGLF4 was used to IP followed by Western blot analysis. 293 















Figure 3.11 Immunofluorescence staining of BGLF4 and 
BZLF1. 2089 cells induced into lytic cycle by transfection of 
BZLF1 and fixed at 24 hours. The cells were stained for 
BGLF4 and BZLF1. Shown are representative micrographs 

















Figure 3.12 Detection of BGLF4. 293 cells were transfected with a BGLF4 
gene encoding plasmid with an HA tag. 2089 cells and BGLF4-KO cells were 
induced into lytic cycle by transfection of BZLF1 and also harvested at the 
same points. Samples were harvested at the indicated time points and 






4.1 The dynamics of EBV lytic replication 
In this project, we originally set out to examine if EBV utilized the DDR proteins to help replicate the 
viral genome efficiently, as seen in several different viruses including adenovirus, herpes simplex 
virus and polyomaviruses (reviewed by Turnell and Grand, 2012). Our chosen model to examine this 
question was primary differentiated tonsillar epithelial cells because EBV is naturally lytic in these 
cells (Feederle et al, 2007). The major advantage of this model is that cells do not require artificial 
lytic cycle induction techniques, for instance chemical induction (e.g.5-azacytidine and sodium 
butyrate). We confirmed that the viral lytic cycle was indeed induced in these cells immediately 
following EBV infection (figure 3.1C). However, due to circumstances beyond our control, including 
difficulty in obtaining the tonsils in a timely manner, bacterial infection and dramatic loss of cells 
during fluorescently activated cell sorting (FACS), we were unable to obtain further meaningful 
results with the primary epithelium. 
The gene expression pattern in the infection of primary differentiated tonsillar epithelial cells varies 
greatly from our 2089 model of lytic replication. 2089 cells require the transfection of a BZLF1 
expression vector leading to the over-expression of BZLF1 protein which continues to activate 
downstream lytic gene promoters. This is why we see a continual increase in lytic gene expression 
over time whereas our primary cell infections undergo a much earlier and shorter lytic event which 
peaks possibly even earlier than 24 hours post infection. Considering the immunofluorescence at the 
single cell level, we see a very dynamic process. Despite all cells being fixed at 24 hours post 
induction, it is not necessarily true that all transfected cells begin lytic cycle synchronously. This is 
exemplified by the pan-nuclear staining seen in figures 3.4 and 3.5 in certain panels, compared to 
the punctate staining seen in others, which are probably images taken slightly before or after the 
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formation of replication compartments. It is also worth noting that not all induced cells will undergo 
complete lytic cycle i.e. only expressing some lytic proteins but not all (data not shown) which brings 
uncertainty to EBV and DDR co-localisation studies. 
 
4.2 The requirement for the DNA damage response during lytic cycle  
The recruitment of HR proteins to EBV replication compartments has been reported and speculated 
to be involved in the repair of viral DNA following damage. In 2009, Kudoh et al showed the co-
localisation of Mre11, Nbs1 and Rad51 with the early viral proteins BALF2 and BMRF1. They also 
showed that RPA, whilst phosphorylated at its DNA damage associated sites, localised to the same 
sites within the nucleus to interact with BMRF1. This work followed the observation that both p53 
and ATM associated with viral replication compartments in a latently infected marmoset B cell line 
(Kudoh et al, 2005). This evidence was reinforced by the binding of pRPA and Mre11 to the BALF5 
gene and the BZLF1 promoter detected by chromatin-immunoprecipitation.  
We set out to examine the ability of EBV to induce a DDR to assist its replication during lytic cycle in a 
human cell line.  However, this could not be determined due to the activation of the DDR following 
transfection of foreign viral DNA in our control. This makes the data difficult to interpret and we are 
unable to determine whether the response observed is induced in any way by the direct action of 
viral lytic proteins. We also observed phosphorylation of CHK2 at 0 hours before any transfection has 
been carried out. This indicates an inappropriate damage response is occurring with no stimuli; 
possibly due to the model we are using as 293 cells are transformed by adenovirus E1 region with 
E1A and E1B proteins constitutively expressed. AdE1A and AdE1B55K have known involvement with 
the DDR, for example, being responsible for the up-regulation of p53 expression. A key difference is 
the phosphorylation of Nbs1 in the control cells not present in our lytic cells suggesting that the virus 
is possibly preventing the activation of the MRN complex. ATM targets p53, CHK2, H2AX and ATM 
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itself have been shown to be phosphorylated within 48 hours of EBV lytic reactivation, but again in a 
marmoset system. Interestingly, this study also showed a lack of ATR target activation (i.e. no CHK1 
phosphorylation). 
We hypothesised that components of the DDR would co-localise with viral proteins within replication 
compartments in our human 2089 model based upon current understanding of the relationship. We 
therefore optimized the antibodies for the proteins we chose to examine on gamma-irradiated cells 
to ensure the formation of damage foci could be differentiated from background expression. Co-
localisation was largely unseen in our experiments with the notable exception of pRPA. Despite its 
failure to interact with BMRF1 and BALF2 in our co-IP assays, it still may be loaded onto newly 
synthesised viral DNA as suggested in previous reports (Kudoh et al, 2009). The problem here may be 
due to an insufficient level of interaction between the two proteins at 24 hours but even over-
expression of the viral proteins in 293 proteins yielded the same result. However, an interaction 
between the viral mRNA export factor (BMLF1) and RPA is indicated by our data (figure 3.6D) but this 
will need to be verified by a co-IP with the reverse antibody.  We showed phosphorylation of ATM 
but failed to show clear co-localisation at viral replication centres but most surprisingly there 
appeared to be little foci recruitment for Rad50 or Rad51. The data here suggests that EBV is not 
using cellular repair proteins during lytic cycle but there is a strong relationship with RPA. SV40 is 
known to utilise RPA, via large T antigen, in order to replicate its DNA (Melendy and Stillman, 1998). 
The increasing presence of RPA correlates to increases in levels of SV40 DNA replication (Wang et al, 
2000). As RPA has multiple functions, it could be involved with a DNA replication function rather than 
DNA repair in the context of EBV based on the observation made here. This theory is supported by 
the lack of ATR substrate activation in previous studies described above. 
EBV lytic reactivation, in certain latently infected cell lines, can occur by various methods such as 
radiation and chemotherapy agents both of which are DDR inducing stimuli (Westphal et al, 2002; 
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Feng et al, 2000). It has been proposed that EBV lytic reactivation is a p53 dependent event in 
epithelial cell lines (Hagemeier et al, 2011). However, it also been shown that p53 is tagged by 
ubiquitin for proteasome mediated degradation induced by BZLF1 so the relationship is not obvious 
(Sato et al, 2009). The function of another central DDR kinase, ATM, is also under investigation for its 
involvement in EBV lytic cycle. Previous studies report that ATM inhibition (or treatment with the 
exogenous indirect ATM activator Nutlin-3) leads to the inhibition of EBV lytic gene expression 
except, notably, in p53 negative cell lines (Hagemeier, 2012). The same group also showed in 2089 
cells that ATM inhibition did not prevent BZLF1 expression. To follow on from this, we carried out 
these experiments to quantify the level of lytic gene transcripts at various time points and ATMi 
concentrations in order to further understand the relationship. Our data agrees that ATM inhibition 
in 2089 cells does not prevent BZLF1 expression but surprisingly, ATM appeared to be inhibitory to 
lytic gene expression. We stipulate this because with increasing concentrations of ATMi, greater lytic 
gene transcription occurs (figure 3.9). As the expression of genes downstream of BZLF1 correlate 
with BZLF1 expression (although to different extents), we believe this is not a result of direct action, 
or lack of action, by ATM. Hagemeier et al suggest that 2089 is a special circumstance as the 
expression vector-mediated BZLF1 overcomes the need for ATM to activate its promoter relative to 
other cell lines with chemically induced lytic reactivation. However, the trend in our data behaves as 
if a down-regulator of BZLF1 expression has been removed which is not explained by that theory. In 
2089 cells, BZLF1-mediated degradation of p53 has been shown to be important for viral lytic cycle 
due to the capability of p53 to initiate apoptosis (Sato et al, 2009). Our data could be an extension of 
this as ATM targets p53 for downstream activation (which includes the possibility of apoptosis). The 
apparent increase in lytic gene transcripts with increasing concentration of ATMi over time could be 





4.3 Potential implications for LETM1 and BALF2 function 
LETM1 is a H+-Ca2+ exchanger that functions at the inner mitochondrial membrane and contributes to 
the control of Ca2+ influx into mitochondria. Knockout of LETM1 in transgenic mice causes 
deregulated glucose and ATP levels when not lethal (Jiang et al, 2013).  The LETM1 gene is also 
known to be deleted in Wolf-Hirschhorn syndrome (Bergemann et al, 2005).  High Ca2+ levels within 
the mitochondria lead to the opening of a permeability transition pore (PTP). Pro-apoptotic factors 
such as cytochrome c that induce apoptosome formation are released through the PTP. A virus 
undergoing lytic cycle is exposing much more of its genome than in its latent cycle and the cell is 
therefore much more likely to initiate apoptosis. One reason for this is that lytic proteins are highly 
susceptible to antigen processing and presentation on surface MHC molecules to surveying CD4+ T 
cells which induce apoptosis by death receptor signalling. The virus needs to combat this in order to 
replicate itself and release new virions from the infected cell. EBV encodes a protein, which is highly 
efficient at inhibiting apoptosis; BHRF1, a viral Bcl2 homologue. We have shown BALF2 to interact 
with LETM1 during viral lytic cycle in our 2089 cell model. It is therefore possible that BALF2 is 
interacting with LETM1 in order to reduce the influx of Ca2+ into the mitochondria to prevent the 
release of pro-apoptotic factors in order to allow virion production. This would be unusual due to the 
currently understood function of BALF2 as a DNA binding protein but viral proteins are known for 
their multifunctional nature. This certainly warrants further investigation. 
Wolf-Hirschhorn syndrome (WHS) is defined by a deletion in the short arm of chromosome 4 leading 
to the loss of the WHS critical region which includes the LETM1 and WHSC1 (Wolf-Hirschhorn 
syndrome candidate 1) genes (Bergemann et al, 2005; Hajdu et al, 2011). Clinical presentations of 
WHS include immunodeficiency, developmental defects and microcephaly. Some of these symptoms 
are shared with ataxia telangiectasia (A-T) patients, a condition characterised by mutation of the 
ATM gene (Biton et al, 2008). It has been shown that WHSC1 is involved in the DDR with its 
recruitment to sites of DNA damage induced by UV radiation and requirement for CHK2 activation 
51 
 
(Bergemann et al, 2005). LETM1 may also have an unknown function in the DDR due to its 
contribution towards the pathogenesis of WHS when absent. Although our data here does not 
strongly suggest BALF2 is involved with the DDR, other reports have done so. The BALF2 and LETM1 
interaction we report could indicate a role for LETM1 in the DNA damage response. 
 
4.4 The role of BGLF4 during lytic cycle 
BGLF4 has known involvement with the cellular DDR hence its initial investigation for binding 
partners (Li et al, 2011). The MRN complex was chosen for co-IP investigation with BGLF4 as a 
potential target for phosphorylation. Nbs1 appears to interact with BGLF4 which is surprising 
considering data generated in figure 3.2 which suggests Nbs1 phosphorylation was being inhibited 
during lytic cycle. BGLF4 could be responsible for the phosphorylation of RPA as an interaction 
between the two proteins was observed. Again unexpectedly, our data suggests BGLF4 is targeting 
p53 despite previous studies suggesting p53 is degraded in this model of lytic replication. BGLF4 is 
known to phosphorylate BZLF1 hence why it was co-stained with the BZLF1 protein but 
unexpectedly, we did not see any co-localisation. We expect to see the lytic protein within the 
nucleus along with its partners as these are genes associated with viral DNA replication and viral DNA 
packaging. The specificity of the antibody is not wholly trusted. BGLF4 cleavage within the context of 
lytic cycle is a possibility based on figure 3.12. BGLF4 is shown at its theoretical molecular weight 
therefore it is probable that another viral protein is responsible for its cleavage which does not occur 
in EBV negative 293 cells transfected with BGLF4. These findings are novel and have implications on 





4.6 Conclusions and future work 
The dynamics of EBV lytic gene expression in the 2089 cell line differs greatly from a more 
physiologically appropriate model in primary keratinocytes. EBV replication is an earlier and quicker 
process than the 2089 model indicates. 2089 cells also generate a DDR after transfection of foreign 
DNA clouding any detectable DDR induction by viral lytic proteins. The ATR target RPA is associated 
with EBV replication compartments within the cellular nucleus but may only be involved in a DNA 
replication role rather than repair. ATR inhibition could prove insightful. Previous studies showed 
that ATM, Rad50 and Rad51 locate with viral proteins during lytic replication but our model failed to 
reproduce this result. As only a select few out of the numerous DDR proteins have been investigated, 
further co-localisation studies need to be carried out before final conclusions can be made. ATM 
activity is either inhibitory to EBV lytic gene expression or works to induce apoptosis preventing viral 
replication. Collectively, the data presented here suggests that EBV does not rely on ATM or its 
downstream targets to replicate its DNA but does perhaps need the ATR target RPA. The differences 
we see here are due to either one of two possibilities. The first being the abnormal DDR pathways in 
293 cells, due to their method of transformation into a cell line, has affected the way in which the 
virus can interact with it. The second is that previous studies have been largely carried out on 
marmoset cell line containing the B95.8 clone of EBV. We have to be wary of using human antibodies 
on cell lines from other species and interpreting their meaning. Although the different cell lineages 
might express differing DNA damage expression patterns which may contribute to differing 
immunofluorescence imaging. 
BGLF4 is possibly cleaved during lytic cycle by a viral protein either directly or indirectly but a 
candidate is not apparent at present. Such proteolysis is seen with various cellular enzymes as an 
activating mechanism which is a theory that might be appropriate here but the data is preliminary.  
The interaction between BALF2 with LETM1 indicates a novel function for the viral DNA binding 
protein in the regulation of apoptosis if this result can be verified. Ideally, investigation will move to a 
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primary differentiated epithelial cell or plasma cell background for more conclusive data towards 
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6. APPENDICES  




6.2 Appendix II: Primer sequences 
Assay Primer/Probe  
EBV genome 
coordinates * 
Sequence 20x conc. 













Wp/Cp W probe 14564–14588 ACCGAAGTGAAGGCCCTGGACCAAC 10µM 
     
EBNA1 Q 62440–62456 GTGCGCTACCGGATGGC 20µM 
 Y3 48422–48440 TGCCTGAACCTGTGGTTGG 20µM 
 F primer 50099-50115 GGGTGAGGCCACGCTTT 20µM 
 U 55247-55269 CTGCAGCCCAGAGAGTAGTCTCA 20µM 





 U probe 67563–67587 TCCTCTGGAGCCTGACCTGTGATCG 10µM 











GCTTAGCCAGTAACTCAGCGCT 6 µM 
 EBNA2 R 36181-36160 TGCTTAGAAGGTTGTTGGCATG 6 µM 
60 
 
 EBNA2 probe 36127-36153 CCCAACCACAGGTTCAGGCAAAACTTT 10µM 
     
EBNA3A EBNA3A F 82313-82335 CCCCTTAACTCAACCCATTAACC 6 µM 






     
EBNA3B EBNA3B F 83265-83281 TGCCGCTGCAAGAGAGG 20µM 









     
EBNA3C EBNA3C F 88813-88831 TACGCCCCATTCCAACAAG 6 µM 






     
BHRF1 W2 14810-14830 TGGTAAGCGGTTCACCTTCAG 6µM 





 HF 42134-42111 TCCCGTATACACAGGGCTAACAGT 6µM 
 Probe  42067-42097 TGCCAGATCTTGTAGAGCAAGATGGCCTATT 10µM 
     
LMP1 LMP1 F 
168644-
168625 






AAGGCCAAAAGCTGCCAGAT 6 µM 
 



















































GGTTCTCCTGATTTGCTCTTCGT 6 µM 












TCCCTAGAAATGGTGCCAATG 6 µM 
 LMP2A 
166215- GAAGAGCCAGAAGCAGATGGA 6 µM 
62 
 
exon1 R 166195 
















AAAGCACGGCCTCCCG 6 µM 




     
LMP2-TR LMP2-TR F 28-50 ACTTTTCTTCTTGCCCGTTCTCT 6 µM 






     
BZLF1 BZLF1 F 90859-90835 CCCAAACTCGACTTCTGAAGATGTA 20x  
 BZLF1 R 90767-90791 TGATAGACTCTGGTAGCTTGGTCAA custom 
 BZLF1probe 90803-90820 CCCATACCAGGTGCCTTT assay 
     
BRLF1 BRLF1 F 92662-92644 TTGGGCCATTCTCCGAAAC 6 µM 
 BRLF1 R 92581-92590 TATAGGGCACGCGATGGAA 6 µM 
 BRLF1probe 92611-92631 AGACGGGCTGAGAATGCCGGC 10µM 
     
BMLF1 BMLF1 F 71978-71958 CCCGAACTAGCAGCATTTCCT 6 µM 
 BMLF1 R 71805-71824 GACCGCTTCGAGTTCCAGAA 6 µM 
 BMLF1 probe 71941-71955 AACGAGGATCCCGCAGAGAGCCA 10µM 
     
63 
 
BALF1 BALF1 F 
164694-
169676 
GGGCAAAGACACGCACGTA 6 µM 
 BALF1 R 
164615-
164633 
GCCGCGACCAGTAGTCGTA 6 µM 












TGATAGGAGGTAGCGCGTAGGA 6 µM 




     
BARF1 BARF1 F 
165586-
165606 
GGGAGCCTCTCTGTTGCTGTT 6 µM 
 BARF1 R 
165658-
165639 
TTTTCCCAACGCAGGTCACT 6 µM 












GAGGCGACCGTTTTCGAA 6 µM 








GGCTTACCTCGGTTCCCTCTTA 6 µM 
 HF 42111-42134 TCCCGTATACACAGGGCTAACAGT 6 µM 
 BHRF1 probe 42067-42097 AATAGGCCATCTTGCTCTACAAGATCTGGCA 10µM 
64 
 
     
BMRF1 BMRF1F 68078-68098 GAGGAACGAGCAGATGATTGG 6 µM 
 BMRF1R 68147-68130 TGCCCACTTCTGCAACGA 6 µM 
 BMRF1 probe 68104-68127 TGCTGTTGATGCCCAAGACGGCTT 10µM 
     
BNLF2A BNLF2A F 
167015-
166996 
TGGAGCGTGCTTTGCTAGAG 6 µM 
 BNLF2A R 
166946-
166966 







     
BNLF2B BNLF2B F 3482-3463 GGAGTTTCCCCCGATTCAAG 6 µM 
 BNLF2B R 
166748-
166769 




















     
BILF1 BILF1 F 
152353-
152333 
TGCCTTTTGACCCAGAACATG 6 µM 
 BILF1 R 
152282-
152303 
CAACGCCATACCCAAGTGAGT 6 µM 














TCCATCCCCGGGAGTGTAT 6 µM 




     
BNRF1 BNRF1 F 3463-3482 GGAGTTTCCCCCGATTCAAG 6 µM 
 BNRF1 R 
166769-
166748 
AAAGGTCAAAGAACAAGGCCAA 6 µM 
 BNRF1 probe 3486-3508 AGGGCGCAAGTTCTCCGGTACCC 10µM 
     
BVRF2 BVRF2 F 
136089-
136108 
CCACGGCAGTCTACGGTACA 6 µM 
 BVRF2 R 
136188-
136173 
GCGGCATTGGCGTCAT 6 µM 




     
BLLF1/ 
GP350 
GP350 F 77316-77297 AGAATCTGGGCTGGGACGTT 6 µM 
 GP350 R 77478-77496 ACATGGAGCCCGGACAAGT 6 µM 
 GP350 probe 77451-77473 AGCCCACCACAGATTACGGCGGT 10µM 
     
FU F1 50099-50115 GGGTGAGGCCACGCTTT 1µM 
 U1 R 55326-55304 CAGGTCTACTGGCGGTCTATGAT 1µM 
 U probe 55275-55299 TCCTCTGGAGCCTGACCTGTGATCG 10µM 
     
66 
 
LF1 LF1 F 
150962-
150943 
GACTGACTCAGGGCCACATC 20x  








     
LF2 LF2 F 
149269-
149286 
CCGGACCGTCAGCTTGAG 20x  








     
LF3 LF3 F 
140769-
140753 
AGGGCTGGGTCCTGAGA 20x  








     
EBER1 EBER1 F 6654-6674 TGCTAGGGAGGAGACGTGTGT 6 µM 
 EBER1 R 6768-6749 TGACCGAAGACGGCAGAAAG 6 µM 
 EBER1 probe 6710-6736 AGACAACCACAGACACCGTCCTCACCA 10µM 
     
EBER2 EBER2 F 6994-7012 AACGCTCAGTGCGGTGCTA 6 µM 
 EBER2 R 7083-7060 GAATCCTGACTTGCAAATGCTCTA 6 µM 
 EBER2 probe 7014-7034 CGACCCGAGGTCAAGTCCCGG 10µM 
     
BART1-3 BART1-3 F 
149581-
149587 










 BART3 R 
149645-
149626 
TGTGTCCGGTAAACGCCATA 6 µM 




     
BART2-3 BART2-3 F 
146318-
146334 
TCCACTTTGTGTTACAGGTCCG 6 µM 
 BART3 R 
149645-
149626 
TGTGTCCGGTAAACGCCATA 6 µM 




     
GAPDH Spans exons 
 Assay ID hs99999905.m1 FAM/TAMRA   
Applied Biosystems 
20x  




 Assay ID hs99999906.m1 FAM/TAMRA   
Applied Biosystems 
20x  
     
B2M Spans exons 
 Assay ID hs00187842 FAM/TAMRA  
 Applied Biosystems 
20x  
